Evidence map›Paper›PMID 25447125›Full record

ArticleExperimental parasitology2015

Ox40L-Ox40 pathway plays distinct roles in regulating Th2 responses but does not determine outcome of cutaneous leishmaniasis caused by Leishmania mexicana and Leishmania major.

Rashmi Tuladhar, Steve Oghumu, Ran Dong, Allison Peterson, Arlene H Sharpe, Abhay R Satoskar

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Experimental parasitology, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Review
  2. Review
  3. OX40, OX40L and Autoimmunity: a Comprehensive Review.Clinical reviews in allergy & immunology · 2016
    Review
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Rashmi TuladharDepartment of Microbiology, The Ohio State University, Columbus, Ohio, United States.
Steve OghumuDepartment of Oral Biology, The Ohio State University, Columbus, Ohio, United States; Department of Pathology, The Ohio State University, Columbus, Ohio, United States.
Ran DongDepartment of Microbiology, The Ohio State University, Columbus, Ohio, United States.
Allison PetersonBrigham and Woman's Hospital, Harvard Medical Centre, Boston, Massachusetts, United States.
Arlene H SharpeBrigham and Woman's Hospital, Harvard Medical Centre, Boston, Massachusetts, United States.
Abhay R SatoskarDepartment of Microbiology, The Ohio State University, Columbus, Ohio, United States; Department of Oral Biology, The Ohio State University, Columbus, Ohio, United States; Department of Pathology, The Ohio State University, Columbus, Ohio, United States. Electronic address: Abhay.Satoskar@osumc.edu.

Funding

Comprehensive Training in Oral &Craniofacial SciencesT32DE014320 · NIDCR · OHIO STATE UNIVERSITY · PI SHERIDAN, JOHN F · 2001 to 2022
$10.2M
Development of novel therapeutics for a neglected tropical disease leishmaniasisRC4AI092624 · NIAID · OHIO STATE UNIVERSITY · PI KINGHORN, ALAN DOUGLAS, SATOSKAR, ABHAY R · 2010 to 2010
$2.6M
Treatment of cutaneous leishmaniasis using Pentalinon andrieuxii root extractR21AT004160 · NCCIH · OHIO STATE UNIVERSITY · PI SATOSKAR, ABHAY R · 2009 to 2010
$411k
Visualization of CXCR3 allelic usage in vivoR03AI090231 · NIAID · OHIO STATE UNIVERSITY · PI SATOSKAR, ABHAY R · 2010 to 2011
$242k
Treating cutaneous leishmaniasis by radio-frequency induced heat (RFH) therapyR34AI100789 · NIAID · OHIO STATE UNIVERSITY · PI SATOSKAR, ABHAY R · 2012 to 2012
$229k
Chemopreventition and treatment of non-melanoma skin cancer by targeting MIFR03CA164399 · NCI · OHIO STATE UNIVERSITY · PI SATOSKAR, ABHAY R · 2012 to 2013
$153k
NCCIH NIH HHS R21 AT004160NCCIH NIH HHS R21AT004160NCI NIH HHS R03 CA164399NCI NIH HHS R03CA164399NIAID NIH HHS R03 AI090231NIAID NIH HHS R03AI090231NIAID NIH HHS R34 AI100789NIAID NIH HHS R34AI100789NIAID NIH HHS RC4 AI092624NIAID NIH HHS RC4AI092624NIDCR NIH HHS T32 DE014320NIDCR NIH HHS T32DE014320
6 · The paper itself

Abstract

Ox40 ligand (Ox40L)-Ox40 pathway has been shown to enhance Th2 responses and play a role in pathogenesis of cutaneous leishmaniasis (CL) caused by Leishmania major. Using Ox40l(-/-) BALB/c mice we analyzed the role of this pathway in determining the outcome to CL caused by L. mexicana and compared to L. major. Contrary to our expectations, Ox40l(-/-) mice were highly susceptible to both L. major (LV39) and L. mexicana (M379) and developed large non-healing lesions containing parasites comparable to Ox40l(+/+) BALB/c mice. Interestingly, upon in vitro stimulation with Leishmania antigen (LmAg), the lymph node cells from L. major infected Ox40l(-/-) mice produced significantly less IL-4 and IL-10 compared to Ox40l(+/+) mice. L. mexicana infected Ox40l(-/-) and Ox40l(+/+) mice did not show any difference in the production of IL-4 and IL-10. No difference was noted in the amount of Th1 cytokines IFN-ү and IL-12 produced by Ox40l(-/-) and Ox40l(+/+) mice infected with either parasite. These results indicate that the Ox40L-Ox40 pathway promotes Th2 bias only in L. major infection but not L. mexicana infection and this pathway is not critical for susceptibility to CL.

Indexed as

Leishmania majorLeishmania mexicanaAnimalsAntibodies, ProtozoanCytokinesFemaleLeishmaniasis, CutaneousMiceMice, Inbred BALB COX40 LigandReceptors, OX40Th2 CellsVirulenceAntibodies, ProtozoanCytokinesOX40 LigandReceptors, OX40Cutaneous leishmaniasisL. majorL. mexicanaOx40L–Ox40

Identifiers

PMID25447125
PMCPMC4474147

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.